W. Bernal and J. Wendon, Acute liver failure, Curr Opin Anaesthesiol, vol.13, issue.2, pp.113-121, 2000.

G. Szabo and J. Petrasek, Inflammasome activation and function in liver disease, Nat Rev Gastroenterol Hepatol, vol.12, issue.7, pp.387-400, 2015.

I. F. Charo and R. M. Ransohoff, The many roles of chemokines and chemokine receptors in inflammation, N Engl J Med, vol.354, issue.6, pp.610-631, 2006.

F. Marra and F. Tacke, Roles for chemokines in liver disease, Gastroenterology, vol.147, issue.3, p.1, 2014.

Y. Itoh, Clinical significance of elevated serum interferon-inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels, J Viral Hepat, vol.8, issue.5, pp.341-349, 2001.

K. Patel, Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C, Clin Gastroenterol Hepatol, vol.12, issue.12, pp.1-3, 2014.

K. J. Helbig, Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro, J Virol, vol.83, issue.2, pp.836-882, 2009.

M. El-raziky, IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy, J Interferon Cytokine Res, vol.35, issue.8, pp.649-53, 2015.

K. J. Helbig, Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation, Hepatology, vol.39, issue.5, pp.1220-1229, 2004.

J. R. Larrubia, Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection, World J Gastroenterol, vol.14, issue.47, pp.7149-59, 2008.

A. V. Semenov,

Y. Q. Deng, Selected Cytokines Serve as Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients With Normal to Mildly Elevated Aminotransferases, Medicine, issue.45, p.2003

A. Liepelt and F. Tacke, Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases, Am J Physiol Gastrointest Liver Physiol, vol.311, issue.2, pp.203-212, 2016.

F. Hong, Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation, Hepatology, vol.49, issue.6, pp.2055-67, 2009.

Y. Saiman, CXCL12 induces hepatic stellate cell contraction through a calciumindependent pathway, Am J Physiol Gastrointest Liver Physiol, vol.305, issue.5, pp.375-82, 2013.

Y. Liu, Contribution and Mobilization of Mesenchymal Stem Cells in a mouse model of carbon tetrachloride-induced liver fibrosis, vol.5, p.17762, 2015.

X. Ling and K. , Stromal Derived Factor-1/CXCR4 Axis Involved in Bone Marrow Mesenchymal Stem Cells Recruitment to Injured Liver, Stem Cells Int, p.8906945, 2016.

U. M. Gehling, Mobilization of hematopoietic progenitor cells in patients with liver cirrhosis, World J Gastroenterol, vol.16, issue.2, pp.217-241, 2010.

B. S. Ding, Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis, Nature, vol.505, issue.7481, pp.97-102, 2014.

O. Wald, Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus, Eur J Immunol, vol.34, issue.4, pp.1164-74, 2004.

J. M. Burns, A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development, J Exp Med, vol.203, issue.9, pp.2201-2214, 2006.

R. Hromas, Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells, Biochem Biophys Res Commun, vol.255, issue.3, pp.703-709, 1999.

M. Otte, CXCL14 is no direct modulator of CXCR4, FEBS Lett, vol.588, issue.24, pp.4769-75, 2014.

T. Hara and K. Tanegashima, CXCL14 antagonizes the CXCL12-CXCR4 signaling axis. Biomol Concepts, vol.5, pp.167-73, 2014.

P. J. Collins, Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4, FASEB J, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01524423

W. Wang, Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo, Cancer Sci, vol.104, issue.11, pp.1523-1554, 2013.

L. Basset, Interleukin-27 and IFNgamma regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis, J Mol Med (Berl), vol.93, issue.12, pp.1355-67, 2015.

A. Erhardt, CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis, J Immunol, vol.186, issue.9, pp.5284-93, 2011.

H. Yoneyama, Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury, Med Mol Morphol, vol.40, issue.4, pp.191-198, 2007.

L. D. Deleve, X. Wang, and L. Wang, VEGF-sdf1 recruitment of CXCR7+ bone marrow progenitors of liver sinusoidal endothelial cells promotes rat liver regeneration, Am J Physiol Gastrointest Liver Physiol, vol.310, issue.9, pp.739-785, 2016.

Y. Saiman, Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury, Hepatol Res, vol.45, issue.7, pp.794-803, 2015.

G. C. Wilson, CXC chemokine receptor-4 signaling limits hepatocyte proliferation after hepatic ischemia-reperfusion in mice, Am J Physiol Gastrointest Liver Physiol, vol.308, issue.8, pp.702-711, 2015.

J. Li, Neutralization of chemokine CXCL14 (BRAK) expression reduces CCl4 induced liver injury and steatosis in mice, Eur J Pharmacol, pp.120-127, 2011.

P. S. Sung, CXCL10 is produced in hepatitis A virus-infected cells in an IRF3dependent but IFN-independent manner, vol.7, p.6387, 2017.

S. Karakus, SDF-1/CXCL12 and CXCR4 gene variants, and elevated serum SDF-1 levels are associated with preeclampsia, Hypertens Pregnancy, vol.36, issue.2, pp.124-130, 2017.